Summary. The anterograde and retrograde axonal flow of acetylcholinesterase were studied in the sciatic nerve of alloxandiabetic rats after five weeks of experimental diabetes. A slight reduction of the anterograde axonal flow of the enzyme was found in alloxan-diabetic compared to control rats. Sedimentation analysis revealed a major reduction of anterograde axonal flow of the light globular forms of the enzyme (G1 + G2), which are probably conveyed by slow transport. There was also a minor reduction of the anterograde flow of the globular form (34, while no modification of the axonal flow of the heavy asymmetric form A12 was found. Both G4 and AI: molecular forms are conveyed by fast axonal transport. In contrast, no abnormality of the retrograde axonal flow of acetylcholinesterase was observed. Ganglioside treatment antagonized the decline of the anterograde axonal flow of the enzyme in alloxan-diabetic rats. These results are consistent with the view that experimental diabetic neuropathy is associated with axonal transport defects, and suggest a protective effect of ganglioside treatment against neuronal damage(s) related to the diabetic syndrome.
Abnormalities of axonal transport have been implicated in the pathogenesis of experimental diabetic neuropathy [1, 2] . Alterations of the slow axonal transport of radiolabelled proteins have been described in motor and sensory sciatic nerve axons of streptozotocin-diabetic rats [3] [4] [5] [6] [7] . As far as fast anterograde axonal transport is concerned, conflicting results have been obtained. Isotope labelling of protein has shown no change of fast axonal transport velocity in sensory axons of the sciatic nerve of streptozotocin-diabetic rats [3, 4, 8, 22] . With the same technique, however, McLean and Meiri [91 found a reduced velocity of fast transported proteins in sciatic nerve motor axons of diabetic rats. A decreased orthograde accumulation of the transmitter-related enzyme acetylcholinesterase was also found in alloxandiabetic rats [10] . In a previous study of the anterograde axonal transport in the sciatic nerve of the mutant diabetic mouse C57 BL/Ks (db/db), we also described an alteration of the G1-Gz acetylcholinesterase molecular form axoplasmic flow [11] concomitant with the retardation of the slow axonal transport of identified cytoskeletal proteins [12] . The present study was undertaken to ascertain whether such a selective abnormality of the axonal transport of acetylcholinesterase was present in rats rendered diabetic by a single injection of alloxan. Alloxan has been used experimentally to induce diabeteg ever since its toxic effects on B cells in the pancreatic islets were recognized [23] . Peripheral nerve electrophysiological abnormalities in alloxan-diabetic rats were first described by Eliasson [24] . Such nerve conduction changes were not observed in rats, which did not become diabetic after alloxan injection, indicating that these deficits were not due to a direct neurotoxic action of alloxan [241. Subsequent reports showed that neurologic abnormalities induced by alloxan and streptozotocin could be obviated by insulin management [25] [26] [27] .
We also tested the effects of ganglioside treatment on axonal transport abnormalities. Previous studies had shown that ganglioside treatment was effective in restoring electrophysiological and morphological parameters in genetic diabetic mice [13] [14] [15] [16] . Interestingly, the restorative effects of gangliosides were observed at a stage of the disease characterized by the drop in acetylcholinesterase slow transport. Prior to this period ganglioside treatment was ineffective [14] .
Materials and methods
Male albino COBS Sprague-Dawley rats (Charles Rivers) were used for this study. One group was given a single subcutaneous injection of 100 mg/kg alloxan (Sigma, St.Louis, MO, USA) in 100mmol/l citrate-phosphate buffer (pH 4.5). After a week, glycosuria was deter- mined by Glucur-test strips (Boehringer, Mannheim, FRG). In addition, glycaemia was measured at the time of killing by the hexokinase method (Gluco-Quant, Boehringer, Mannheim, FRG). Alloxan-diabetic rats with glycaemic values below 250 mg/dl did not enter the study. A second group of age-matched rats were the untreated controls.
Determinations of A ChE flow
The AChE anterograde and retrograde axonal flow were determined by the test-section method described by Couraud and Di Giamberardino [17] . Briefly, under ether anaesthesia the left sciatic nerves of rats were cut at the mid-femur level and a 2 mm nerve segment was resected to determine the basal level of ACHE. Twenty-four hours later the 2-ram extremity of the proximal and distal stumps, where AChE accumulation was strictly confined, were excised and assayed for AChE content and concentration of molecular forms. Nerve segments were homogenized in 300 lxl of extraction buffer (1 mol/l NaC1, 100 mmol/l phosphate buffer, pH 7.0, 1% Triton X-100; and 1.9 rag/ ml EGTA, 1 mg/ml bacitracin and 0.16 mg/ml benzamidine as protease inhibitors). The homogenates were centrifuged 20rain at 20,000g and 4°C, and usually 20 p3 supernatant was assayed for AChE activity by a slight modification of the Ellman's method [17, 28] using 0.75 mmol/1 acetylthiocholine as substrate and 0A mmol/1 Tetraisoprophylpyrophosphoramide (ISO-OMPA, Sigma, St. Louis, MO, USA) as non-specific cholinesterase inhibitor (one unit AChE represents the quantity of enzyme hydrolyzing I nmol AcThCh/min). The Ellman's buffer, supplemented with 0.t mmol/1 ISO-OMPA and 0.75 mmol/1 acetylthiocholine, was utilized to measure acetylthiocholine spontaneous hydrolysis to correct the enzymatic activity measured in sciatic nerve samples. The remainder of the supernatant was layered on a 5-20% linear concentration gradient of sucrose in extraction buffer and centrifuged 19h at 250,000 g and 4 °C in a SW 41 Beckman rotor (Beckman Instruments, Palo Alto, CA, USA). The gradients were then divided into 60-70 fractions and assayed for AChE activity. The amount of each AChE form was determined from its relative proportion in the sedimentation profile. The accumulation of AChE was calculated on the extremity of the proximal and distal stumps, corrected for the enzymatic concentration present within the intact nerve.
Treatment of diabetic and control rats
Alloxan-diabetic and control rats were randomly subdivided into t'~o groups respectively. The first group, comprising alloxan-diabetic and control rats, received daily intraperitoneal injections of 10 mg/kg of a bovine brain ganglioside mixture (GM1 21%, GDla 39.7%, GDlb 16% and GTIb 19%) for 4 weeks, starting 1 week after the induction of diabetes. The second group of diabetic and control rats received daily intraperitoneal injections of saline.
Statistical analysis
Statistical analysis were performed utilizing the unpaired Student's ttest.
Results

Changes in body weight
Seven-week-old rats entered the study at a starting weight between 175-200 g. Five weeks later, at the time of killing, control rats showed a significant increase in body weight. In contrast, the growth rate of alloxan-diabetic rats was impaired. Serum glucose was raised sub- stantially in all alloxan-treated rats as compared to controls. Ganglioside treatment did not modify these parameters in both groups (Table 1) .
Axonal transport of acetylcholinesterase
After 5weeks of uncontrolled diabetes, the total amount of AChE activity per unit length of sciatic nerve of diabetic rats was not different than controls (Fig. 1 a) . In addition, the sedimentation pattern revealed no alteration in the distribution of the enzymatic activity between the AChE different molecular forms ( Fig. 1 a and  2) .
The anterograde accumulation at a test section showed a 20% reduction in diabetic compared to control rats (Fig. 1 b) . However, the calculation of the relative contribution of the different molecular forms to the total accumulation revealed a dramatic deficit of G1 and G2 molecular form accumulation in diabetic compared to control rats ( Fig. 1 b and 2) . A minor reduction was also observed for G4 and A12 AChE molecular forms. Differences were statistically significant (p < 0.01) only for total, Gt + G2 and for G4 (see Figs. 1 b and 2).
In contrast, no significant quantitative and qualitative reduction of the retrograde axonal flow of the enzyme was measured in alloxan-diabetic rats (Fig. 3) .
Ganglioside treatment modified neither total AChE enzymatic activity in intact sciatic nerves of both diabetic and control rats, nor its distribution between different molecular forms (Fig. 1 a) . The anterograde axonal flow of the enzyme in ganglioside-treated diabetic rats was comparable to control (Fig. 1 b) . In particular, we did not observe a noticeable deficit of accumulation of G1-G2 molecular forms occurring in alloxan-diabetic rats treated with saline. The minor modification of anterograde axonal flow of G4 was no more observable in ganglioside-treated rats. The effect of ganglioside treatment could not be ascribed to the enhancement of AChE enzymatic activity, since the same amount of enzyme accumulated at a test section of both gangliosideand saline-treated control rats (Fig. 1 b) .
Discussion
Our investigation was centered on the effects of ganglioside treatment upon the neurological complications developed in alloxan-diabetic rats. The impairment of the orthograde axonal transport of AChE is a characteristic neuronal deficit in experimental diabetes. A reduction of anterograde axonal flow of AChE was first described by Schmidt et al. [10] ; it was found that, 3-4 weeks after streptozotocin injection, the accumula-tion of the enzyme proximal to a sciatic nerve constriction was reduced by 20%. A similar study on the genetically diabetic mouse C57 BL/Ks (db/db) revealed that such an impairment was due to the selective flow reduction of G1-G2 AChE molecular forms [15] . Our results point to a major impairment of G1-G2 anterograde axonal flow in alloxan-induced diabetic neuropathy. Since G1 and G2 AChE molecular forms are probably conveyed by slow axonal transport [16] , the present results further support the relevance of slow transport impairment in the pathogenesis of experimental diabetic neuropathy [3-7, 8-12, 29] .
On the other hand, the relationship between diabetic neuropathy and fast axonal transport defects is more complex. The G4 and A12 forms of acetylcholinesterase are conveyed by fast axonal transport [17] . We found a minor, but statistically significant, reduction of the G4 AChE molecular form axonal flow, while no statistically significant alteration of A12 flow was found. Such a deficit of G4 axonal flow was not observed in the genetically diabetic mouse throughout its lifetime [11] . The genetic mouse develops a gradual, progressive neuropathy over several months [11] , while alloxan and streptozotocin cause neurological alterations within a few days after intoxication [3] . However, Swiss albino mice poisoned with alloxan develop transport deficits identical to rats, i.e. the axonal flow of G1-G2 and G4 AChE molecular forms is reduced in a similar way (Vitadello et al., unpublished observations). These facts suggest that G4 flow impairment may not be speciesrelated, but rather be dependent upon the mode of onset of the diabetic syndrome.
The observed reduction of anterograde axonal flow of AChE can be attributed either to a reduced transport velocity or to a reduced clearance (quantity of transported enzyme per unit length of nerve). At present we cannot decide between these two hypotheses, although several reports showing an impairment of transport velocity might favor the former one [3-7, 12, 29] .
Ganglioside treatment prevented the onset of AChE axonal transport deficits, confirming previously reported positive effects of ganglioside treatment on electrophysiological and morphometric parameters in genetic and alloxan-diabetic animals [13] [14] [15] [16] . In particular, the beneficial effects of ganglioside treatment in the genetically diabetic mouse C57 BL/Ks (db/db) were shown only in 180-day-old diabetic mice [13, 14, 16] , i.e. at a time when the axonal flow of G1 and G2 AChE molecular forms was altered [11] . Ganglioside effects were not due to an enhancement of AChE enzymatic activity because: (a) basal AChE activity level and molecular form distribution were not modified by ganglioside treatment in both diabetic and control rats; (b) no modification of AChE accumulation was observed in ganglioside-treated control rats. However, it is possible that the positive effect of ganglioside treatment was due to the stabilization of the clearance of the enzyme, if it was reduced in diabetic animals. 257 Gangliosides, GMt in particular, have a regrowth stimulating effect and/or a protective effect against neurotoxin induced retrograde degeneration [18] . It has been previously reported that ganglioside treatment of diabetic neuropathy in C57 BL/Ks (db/db) mice promoted a significant improvement of nerve conduction velocity and a normalization of axonal size [14] . It has been suggested that alterations of axonal morphology and axonal transport are correlated in experimental diabetic neuropathy [29] . Therefore, the improvement of axonal size might depend on the improvement of axonal flow after ganglioside treatment. The molecular mechanisms by which gangliosides act are still unclear, although some experimental conditions have suggested that these molecules may have a decay-preventing activity on neuronal functions. Sodium loading and hypoxia experiments performed with ex vivo neuromuscular preparations showed that gangliosides increased the resistance to ionic disbalances and low oxygen level [19] [20] [21] . It is conceivable that the same basic mechanisms are responsible for the prevention of AChE transport deficits occurring in experimental diabetic neuropathy.
